Literature DB >> 25963595

Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.

Maja D Andersen1, Peter Kamper1, Patricia S Nielsen2, Knud Bendix2, Rikke Riber-Hansen2, Torben Steiniche2, Stephen Hamilton-Dutoit2, Michael Clausen1, Francesco d'Amore1.   

Abstract

The tumour microenvironment in classical Hodgkin's lymphoma (cHL) is characterised by a minor population of neoplastic Hodgkin and Reed-Sternberg cells within a heterogeneous background of non-neoplastic bystanders cells, including mast cells. The number of infiltrating mast cells in cHL has been reported to correlate with poor prognosis. We used immunohistochemistry to assess the degree of tumour-infiltrating mast cells in cHL tissue microarrays and correlated this with clinico-pathological features and prognosis in a cohort of homogeneously treated patients with Hodgkin's disease. A high degree of tumour mast cells was associated with nodular sclerosis (NS) subtype histology (P = 0.0002). Moreover, the number of mast cells was inversely correlated with the numbers of CD68+ and CD163+ macrophages (P = 0.0001 and P = 0.003, respectively) and with the number of granzyme+ cytotoxic cells (P = 0.004). The degree of mast cell infiltration was not a prognostic factor in cHL of nodular sclerosis subtype. In contrast, in mixed cellularity cHL a high number of intratumoral mast cells correlated with significantly poorer outcome both in terms of overall (P = 0.03) and event-free survival (P = 0.01). Further studies are warranted into the biological mechanisms underlying this adverse outcome and their possible therapeutic implications.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  classical Hodgkin's lymphoma; mast cells; mixed cellularity subtype; prognosis; tumour microenvironment

Mesh:

Substances:

Year:  2015        PMID: 25963595     DOI: 10.1111/ejh.12583

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  19 in total

Review 1.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

2.  High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome.

Authors:  Peter Hollander; Peter Kamper; Karin Ekstrom Smedby; Gunilla Enblad; Maja Ludvigsen; Julie Mortensen; Rose-Marie Amini; Stephen Hamilton-Dutoit; Francesco d'Amore; Daniel Molin; Ingrid Glimelius
Journal:  Blood Adv       Date:  2017-08-08

3.  Role of mast cells in fibrosis of classical Hodgkin lymphoma.

Authors:  Shoko Nakayama; Taiji Yokote; Nobuya Hiraoka; Uta Nishiwaki; Toshiaki Hanafusa; Yasuichiro Nishimura; Motomu Tsuji
Journal:  Int J Immunopathol Pharmacol       Date:  2016-04-19       Impact factor: 3.219

4.  CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.

Authors:  Hinrich P Hansen; Ahmad Trad; Maria Dams; Paola Zigrino; Marcia Moss; Maximilian Tator; Gisela Schön; Patricia C Grenzi; Daniel Bachurski; Bruno Aquino; Horst Dürkop; Katrin S Reiners; Michael von Bergwelt-Baildon; Michael Hallek; Joachim Grötzinger; Andreas Engert; Adriana F Paes Leme; Elke Pogge von Strandmann
Journal:  Oncotarget       Date:  2016-05-24

Review 5.  Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Mansour Seaf; Giancarlo Marone; Francesca Levi-Schaffer; Gianni Marone
Journal:  Front Med (Lausanne)       Date:  2017-07-24

Review 6.  Are Mast Cells MASTers in Cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Giancarlo Marone; Raffaella Iannone; Gianni Marone; Francescopaolo Granata
Journal:  Front Immunol       Date:  2017-04-12       Impact factor: 7.561

7.  Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.

Authors:  Xiaobo Bo; Jie Wang; Tao Suo; Xiaoling Ni; Han Liu; Sheng Shen; Min Li; Yueqi Wang; Houbao Liu; Jiejie Xu
Journal:  BMC Cancer       Date:  2018-03-21       Impact factor: 4.430

Review 8.  The Microenvironment in Epstein-Barr Virus-Associated Malignancies.

Authors:  Geok Wee Tan; Lydia Visser; Lu Ping Tan; Anke van den Berg; Arjan Diepstra
Journal:  Pathogens       Date:  2018-04-13

Review 9.  Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma.

Authors:  Eleonora Calabretta; Francesco d'Amore; Carmelo Carlo-Stella
Journal:  Int J Mol Sci       Date:  2019-11-05       Impact factor: 5.923

10.  Time Trends in Rates of Hodgkin Lymphoma Histologic Subtypes: True Incidence Changes or Evolving Diagnostic Practice?

Authors:  Sally L Glaser; Christina A Clarke; Theresa H M Keegan; Ellen T Chang; Dennis D Weisenburger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-07-27       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.